India has announced its national list of essential medicines (NLEM) 2015, which covers a total of 376 drugs across 30 therapeutic segments, including those such as sofosbuvir, pegylated interferon alfa 2a and 2b, raltegravir, trastuzumab, and rituximab, as against 348 medicines across 27 segments listed in NLEM 2011.
While the key objective of the NLEM is to promote the rational use of drugs and optimum use of resources available for health care delivery, medicines on the NLEM are typically subject to price caps in India
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?